Cash and cash equivalents amounted to EUR 300.2 million at the end of March 2024, decreasing from EUR 402.5 million at the end of 2023. In the first three months of 2024, cash used in operations was mainly allocated to the last payments related to the termination of raw material commitments for the first-generation vaccine, amounting to a total of EUR 52 million. Looking forward there will be no further raw material payments related to CVnCoV. The remaining cash spend was mainly related to ongoing R&D activities. In the second quarter of 2024, the company expects to fully settle all remaining CMO-related provisions stemming from CVnCoV. The company reaffirms its cash runway into the fourth quarter of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVAC:
- CureVac price target lowered to $14 from $18 at UBS
- Curevac’s Market Forecast Risks: Miscalculations and Trial Participant Challenges Threaten Profitability
- CureVac downgraded to Market Perform from Outperform at Leerink
- CureVac N.V. Reports Strong 2023 Finances and Strategic Advances
- CureVac Launches Study for H5N1 Influenza Vaccine
